Meridian Bioscience Provides FY 2013 Guidance | GenomeWeb

NEW YORK (GenomeWeb News) - Meridian Bioscience today provided financial guidance for fiscal-year 2013 and reaffirmed its 2012 guidance given just a month ago.

The Cincinnati-based diagnostics firm said that it expects revenues for its fiscal year ended Sept. 30, 2013, to be in the range of $190 million to $195 million. It also anticipates per-share diluted earnings to be between $.86 and $.91.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

DuPont teams with genome editing firm Caribou Biosciences for agricultural applications of the technology.

A blogger reviews her experience learning about her gut microbiome by shipping a sample to uBiome.

In Science this week: ancient Ethiopian genome indicates greater Eurasian backflow into Africa, sequencing to diagnose cutaneous T cell lymphoma, and more.

The US House of Representatives science committee has passed a bill to require NSF to ensure it only funds projects that are in the national interest.